Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 9/20 | 0.53 |
| ▸ | ITK | Q08881 | 9/20 | 0.53 |
| ▸ | SRC | P12931 | 8/20 | 0.53 |
| ▸ | KIT | P10721 | 7/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.53 |
| ▸ | TTK | P33981 | 2/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.53 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.53 |
| ▸ | BTK | Q06187 | 3/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038359 | 0.90 | BTK (0.59) | FLT3ITKSRCKITAURKA | |
| SCHEMBL1038537 | 0.83 | BTK (0.56) | FLT3ITKSRCBTK | |
| SCHEMBL1038542 | 0.81 | BTK (0.48) | AURKATTKAURKBINCENPBTK | |
| SCHEMBL1042485 | 0.80 | BTK (0.43) | FLT3ITKSRCKITBTK | |
| SCHEMBL3740333 | 0.80 | AURKA (0.39) | ITKKITAURKATTKAURKB | |
| SCHEMBL12956114 | 0.80 | BTK (0.50) | FLT3ITKSRCKITBTK | |
| SCHEMBL13044255 | 0.80 | BTK (0.42) | FLT3ITKSRCKITBTK | |
| SCHEMBL3740338 | 0.80 | AURKA (0.37) | AURKATTKAURKBINCENPBTK | |
| SCHEMBL1423845 | 0.79 | BTK (0.41) | AURKATTKAURKBINCENPBTK | |
| SCHEMBL1041847 | 0.79 | BTK (0.52) | FLT3ITKSRCBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079726-B1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2079726-B1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-7838523-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838523-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838523-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008033857-A2 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | FLT3 30/4885ITK 487/4885SRC 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.